Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

Aagshsg Dec. 5 at 12:39 PM

$SCYX what is next catalyst here? Don't they need to pump Stock over $1 soon?

0 · Reply

SMARTR8 Dec. 5 at 12:14 AM

If you haven’t joined the Discord yet — now’s the time. 🤝 I’ll still post here, but the real action is happening inside the SMARTR8 server: • Real plays (free + VIP 💎) • Education that actually matters Everyone’s welcome — don’t watch from the sidelines. $OPEN from 0.55 and called it multiple on ST too. ✅️ I have order proof for every trade I EVER said I took. $NIXX I want more here 👀 $SCYX sooner than later 🤫 $IQST Give me reasons not to like this one 👉 Link in bio Link in bio

0 · Reply

Pommy1 Dec. 4 at 8:58 PM

$SCYX it’s f shame when u see the volume of approved drug n gsk involved in it.pos

1 · Reply

Pommy1 Dec. 4 at 1:12 PM

$SCYX David where r ur European friends.u spend lot of our money there.

0 · Reply

Cosmicshiva Dec. 4 at 9:50 AM

$SCYX ⏱️👀♉🐂🙏😎

0 · Reply

Pommy1 Dec. 3 at 6:52 PM

$SCYX another week no http://luck.still in shit hole

0 · Reply

kirthan5 Dec. 3 at 2:28 PM

$SCYX have anyone seen a stock with zero volume

0 · Reply

Pommy1 Dec. 2 at 5:22 PM

$SCYX looks like gsk scammed David http://lol.they ain’t give him money they ain’t gona start production

1 · Reply

Pommy1 Dec. 1 at 8:52 PM

$SCYX lol wt to say

1 · Reply

XZeroDelta Dec. 1 at 12:59 PM

$SCYX Here is part #4: * Cash Burn: Investors expect the company to spend this money on operations (R&D, salaries) rather than returning it to shareholders. Scynexis has stated this cash provides a runway for over 2 years, meaning they will be "burning" this cash balance down over time. * Market Sentiment: The transfer to the Nasdaq Capital Market (or fear of delisting) often scares away institutional investors, creating selling pressure that drives the price below its rational book value. Summary If you look strictly at the balance sheet, Scynexis is "on sale." Buying the stock at $0.69 is mathematically similar to buying a wallet containing $1.15 (net) to $1.49 (gross) for roughly 70 cents. Here is a potato due to the long thread:

1 · Reply

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Nov 5, 2025, 4:20 PM EST - 4 weeks ago

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 15, 2025, 8:00 AM EDT - 7 weeks ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Sep 4, 2025, 8:30 AM EDT - 3 months ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Aug 13, 2025, 4:30 PM EDT - 4 months ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 28, 2025, 8:30 AM EDT - 6 months ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

Mar 12, 2025, 5:08 PM EDT - 9 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 10, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 9, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 2, 2024, 10:04 AM EDT - 1 year ago

Scynexis: Update Following Restructuring Of GSK Deal

Mar 28, 2024, 4:01 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Jan 29, 2024, 5:15 PM EST - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 8, 2024, 4:00 AM EST - 2 years ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 5, 2024, 8:30 AM EST - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 4, 2024, 7:00 AM EST - 2 years ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 2 years ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 28, 2023, 9:00 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 22, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:46 PM EST - 2 years ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:15 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 30, 2023, 8:30 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 29, 2023, 7:50 PM EST - 2 years ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 2 years ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 2 years ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 19, 2023, 11:45 PM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 17, 2023, 11:15 AM EST - 2 years ago

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 15, 2023, 1:15 PM EST - 2 years ago

SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc.

Aagshsg Dec. 5 at 12:39 PM

$SCYX what is next catalyst here? Don't they need to pump Stock over $1 soon?

0 · Reply

SMARTR8 Dec. 5 at 12:14 AM

0 · Reply

Pommy1 Dec. 4 at 8:58 PM

$SCYX it’s f shame when u see the volume of approved drug n gsk involved in it.pos

1 · Reply

Pommy1 Dec. 4 at 1:12 PM

$SCYX David where r ur European friends.u spend lot of our money there.

0 · Reply

Cosmicshiva Dec. 4 at 9:50 AM

$SCYX ⏱️👀♉🐂🙏😎

0 · Reply

Pommy1 Dec. 3 at 6:52 PM

$SCYX another week no http://luck.still in shit hole

0 · Reply

kirthan5 Dec. 3 at 2:28 PM

$SCYX have anyone seen a stock with zero volume

0 · Reply

Pommy1 Dec. 2 at 5:22 PM

$SCYX looks like gsk scammed David http://lol.they ain’t give him money they ain’t gona start production

1 · Reply

Pommy1 Dec. 1 at 8:52 PM

$SCYX lol wt to say

1 · Reply

XZeroDelta Dec. 1 at 12:59 PM

1 · Reply

XZeroDelta Dec. 1 at 12:57 PM

$SCYX Here is part #3: Scenario B: Net Cash (Liquidation) Value (This assumes you use the cash to pay off every single liability on the books first.) * Total Liabilities (Q3 2025): $14.6 Million (Includes accounts payable, accrued expenses, lease liabilities, etc. Notably, they have cleared their convertible debt.) * Net Cash: $62.7M (Cash) - $14.6M (Liabilities) = $48.1 Million Why is the stock trading so low? You might wonder why a company with $1.49 in cash per share is trading at $0.69. This is a common phenomenon in biotech ("trading below cash") and usually happens for two reasons:

0 · Reply

XZeroDelta Dec. 1 at 12:56 PM

$SCYX Here is part #2: The Calculation Breakdown Here is the step-by-step math using Scynexis's official Q3 2025 filing and the announced GSK terms. 1. Total Pro Forma Cash (The "Pot of Gold") We combine the cash they already have with the guaranteed cash coming from GSK. * Cash on Hand (Sept 30, 2025): $37.9 Million (Includes cash, cash equivalents, and short-term investments) * Incoming GSK Payment (Q4 2025): $24.8 Million (Includes the $22M settlement + ~$2.8M for wind-down costs) * Total Pro Forma Cash: $62.7 Million 2. The Share Count (The Divisor) * Shares Outstanding: ~42.0 Million (Specifically 41,956,724 shares as of Sept 30, 2025) 3. Value Per Share Scenarios Scenario A: Gross Cash per Share (This assumes the company is valued purely on its liquidity, ignoring liabilities.)

0 · Reply

XZeroDelta Dec. 1 at 12:54 PM

$SCYX Using Gemini 3 to calculate Scynexis's "intrinsic value" lead to this response. Here is part #1: "Based on the most recent financial data from Q3 2025 and the terms of the GSK settlement, Scynexis currently holds significantly more cash per share than its stock price reflects. Here is the breakdown of the company's "intrinsic value" based purely on its liquid assets and the incoming payment. The Bottom Line Scynexis has an estimated Gross Cash Value of ~$1.49 per share. Even if you pay off all company debts and liabilities immediately (Net Cash), the value is approximately ~$1.15 per share. With the stock currently trading around $0.69, the company is effectively trading at a 40-50% discount to the cash it will hold in the bank by the end of 2025.

0 · Reply

SMARTR8 Nov. 30 at 4:07 PM

$BYND, $OSRH, $IQST, $HUBC , $SCYX A tight list of names I’ll be watching closely this week — a mix of momentum + undervalued setups showing early strength. 👀 Full updates and deeper breakdowns get shared inside the Vault 💎 👉Link in bio

0 · Reply

MrTicker Nov. 28 at 3:23 PM

$SCYX 10k sell order at .74 , It's been there for a few days.

1 · Reply

SMARTR8 Nov. 28 at 3:14 PM

$TELO time to wake up ⏰️😌 $SCYX ready 2 go 🤫💎 Check my profile - I bet you haven't seen a better 2025 performance yet 🤝 I want YOU to join the WINNING team 💎

1 · Reply

SMARTR8 Nov. 28 at 3:06 PM

$OSRH x $SCYX ONE TEAM ✅️

0 · Reply

SMARTR8 Nov. 28 at 3:03 PM

$SCYX We are all aboard. You may start moving up now 💎🤝

0 · Reply

MrTicker Nov. 28 at 2:57 PM

$SCYX For those that didn't see the news 9 days ago and the price stayed flat. Possible run to close out the month. 08:24 AM EST, 11/19/2025 (MT Newswires) -- Scynexis(SCYX) said Wednesday it has completed the transfer of the new drug application for Brexafemme, or ibrexafungerp, to GSK (GSK). The transfer allows GSK to begin working with the US Food and Drug Administration on a plan to relaunch Brexafemme for vulvovaginal candidiasis and refractory vulvovaginal candidiasis in the US, Scynexis(SCYX) Chief Executive Officer David Angulo said. Following a relaunch, Scynexis(SCYX) said it could receive up to $145.5 million in annual net sales milestones as well as low to mid-single-digit royalties on net sales.

1 · Reply

Lovemypicks Nov. 26 at 4:15 PM

$SCYX

1 · Reply

Iightning Nov. 26 at 6:12 AM

1ightning® Options Trade Alert (Actionable) | Buy $SCYX Dec 19 $2 Call | Enter: $0.05 Exit: $0.08 | Profit: 56.64% ROI | https://1ightning.com

0 · Reply

kirthan5 Nov. 25 at 10:01 PM

$SCYX Lowest volume in weeks , this looks like scary risky .. what's going on ? Still a bull here

2 · Reply

Market Cap	27.57M
Revenue (ttm)	3.75M
Net Income (ttm)	-21.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-567.73%
Debt to Equity Ratio	0.00

Volume	153,900
Avg Vol	601,600
Day's Range	N/A - N/A
Shares Out	41.97M
Stochastic %K	48%
Beta	1.37
Analysts	Strong Sell
Price Target	$3.67